Solos Endoscopy Inc (OTCMKTS:SNDY) Gets A Pump

Solos Endoscopy Inc (OTCMKTS:SNDY) has popped up on our radar as it has caught the attention of several newsletters. February was an active month for SNDY and it became a volume leader on the OTC markets. To kick off March, SNDY has caught the attention of the "Wolf Of Stocks" and the Epic Penny Stock Group. Epic is touting SNDY as a low floater on the verge of breaking out. Epic is picking up where Damn Good Penny Stocks left off last month.Solos Endoscopy describes itself as having "recently celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions."For a company that's been in business for 25 years, it doesn't have much to show for. Its latest filings showed just $78k in revenues and a net loss of $58k for the quarter ended March 31, 2015. The company ended 2014 with just $3k in cash on its balance sheet. Total current assets amounted to $318k, but there was $390k in total current liabilities.Last month, Solos announced that it had renewed the Establishment Registration & Device Listing of its endoscopic instruments with the U.S. Food and Drug Administration (FDA). Solos Endoscopy instruments are registered and approved with the FDA; the FDA approval also covers the entire MammoView instrument line. The company markets over 200 items to the endoscopic market and is continuing the development of products that will enhance the ability of medical professionals to perform minimally invasive surgical techniques. President Robert Segersten said:

"Management believes that renewal of its establishment registration with the FDA along with the capital restructuring was necessary to maintain the value of our company and position us for growth. Solos has been recognized nationwide by physicians who use their instruments. It is our hope that this recognition will lead to increased sales worldwide."

Last September, Solos completed the fifth reverse split in its history. The company touted it as a capital restructuring. Digging deeper, we found that "Solos has incurred net losses through September 30, 2015 in the amount of $9,380,621. This factor raises doubt as to Solos’s ability to obtain debt and/or equity financing and achieve profitable operations. Solos’s management intends to raise additional operating funds through equity and/or debt offerings. However, there can be no assurance management will be successful in its endeavors. Ultimately, Solos will need to achieve profitable operations in order to continue as a going concern. "The company does have some interesting products that might allow them to keep going and raise additional funds. The MammoView Breast Endoscopy System is an FDA Approved system that assists in providing women the best prognosis for recovery by detecting breast cancer sooner than conventional methods. This system allows physicians to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods.Last year, SNDY's MammoView Ductoscopy System was utilized in a live demonstration by Dr. Sheldon Feldman, MD FACS from Columbia University at the Dr. Susan Love Research Foundation Symposium on the Breast before dozens of physicians from around the world who came to learn about the new technical approaches to the study. SNDY also offers a complete line of state-of-the-art Camera Systems, illumination devices, laparoscopic instruments, scopes, and it's line of SteriTAP endoscopic instruments.It's important for new investors to realize that SNDY was trading at just $.021 two weeks ago. While the Epic Group is powerful and will no doubt pop shares of SDNY, we urge a bit of caution as short sellers and investors that bought in at cheaper prices sell. We will be updating Insider Financial as soon as we know more. For continuing coverage on SNDY and our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in SNDY and have not been compensated for this article.